MX360390B - Inhibidores de la proteina 90 de choque termico (hsp90). - Google Patents

Inhibidores de la proteina 90 de choque termico (hsp90).

Info

Publication number
MX360390B
MX360390B MX2013011532A MX2013011532A MX360390B MX 360390 B MX360390 B MX 360390B MX 2013011532 A MX2013011532 A MX 2013011532A MX 2013011532 A MX2013011532 A MX 2013011532A MX 360390 B MX360390 B MX 360390B
Authority
MX
Mexico
Prior art keywords
compounds
formulae
compound
formula
effective amount
Prior art date
Application number
MX2013011532A
Other languages
English (en)
Other versions
MX2013011532A (es
Inventor
Sun Weilin
Taldone Tony
Patel Pallav
Chiosis Gabriela
Original Assignee
Sloan Kettering Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer Res filed Critical Sloan Kettering Inst Cancer Res
Publication of MX2013011532A publication Critical patent/MX2013011532A/es
Publication of MX360390B publication Critical patent/MX360390B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La descripción se refiere a compuestos de las fórmulas (lA) y (IB) y slaes farmacéuticamente aceptables de los mismos, en donde Z1, Z2, Z3, Xa, Xb, Xc, Xd, Y, X2 y X4, son como se definen en la presente, a composiciones que comprenden una cantidad efectiva de un compuesto de la fórmula (IA) y/o (IB), y a métodos para tratar y prevenir una condición, este cancer que sobreexpresa Her-cinasas, que comprende administrar a un paciente en necesidad de lo mismo una cantidad terapéuticamente efectiva de un compuesto de la fórmula (lA) y/o (IB). La descripción se refiere adicionalmente a compuestos de las Fórmulas (lA) y/o (IB) en los cuales X2 es un grupo saliente para intrudicir un átomo radiomarcado, tal como 124I o 131I y a métodos para usar estos compuestos en la preparación de compuestos radiomarcados, particularmente para el uso en formación de imágenes.
MX2013011532A 2011-04-05 2012-04-05 Inhibidores de la proteina 90 de choque termico (hsp90). MX360390B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472061P 2011-04-05 2011-04-05
PCT/US2012/032371 WO2012138894A1 (en) 2011-04-05 2012-04-05 Hsp90 inhibitors

Publications (2)

Publication Number Publication Date
MX2013011532A MX2013011532A (es) 2014-08-22
MX360390B true MX360390B (es) 2018-10-31

Family

ID=48166734

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011532A MX360390B (es) 2011-04-05 2012-04-05 Inhibidores de la proteina 90 de choque termico (hsp90).

Country Status (11)

Country Link
US (2) US9346808B2 (es)
EP (1) EP2694505B1 (es)
JP (1) JP6266506B2 (es)
KR (1) KR102010222B1 (es)
CN (1) CN103582642B (es)
AU (1) AU2012240077C1 (es)
BR (1) BR112013025634A2 (es)
CA (1) CA2832530C (es)
EA (1) EA201391334A1 (es)
MX (1) MX360390B (es)
WO (1) WO2012138894A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
CA2656202C (en) 2006-06-30 2018-01-16 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
LT2486039T (lt) 2009-10-07 2016-10-10 Sloan Kettering Institute For Cancer Research Purino dariniai, naudingi kaip hsp90 slopikliai
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
KR101984480B1 (ko) 2011-04-05 2019-05-31 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 억제제
MX2014000292A (es) 2011-07-08 2015-03-06 Sloan Kettering Inst Cancer Usos de inhibidores etiquetados hsp90.
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
MX370664B (es) 2013-08-16 2019-12-19 Memorial Sloan Kettering Cancer Center Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
AU2014386214B2 (en) 2013-12-23 2020-05-21 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
US10617772B2 (en) 2014-09-17 2020-04-14 Memorial Sloan Kettering Cancer Center Hsp9O-targeted inflammation and infection imaging and therapy
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
JP7132848B2 (ja) 2015-10-05 2022-09-07 メモリアル スローン ケタリング キャンサー センター 癌の治療のための合理的併用療法
US20210161902A1 (en) * 2017-06-23 2021-06-03 Samus Therapeutics, Inc. Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841549D1 (de) 1997-05-14 2010-04-22 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
WO2000061578A1 (en) 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
CA2426952C (en) 2000-11-02 2012-06-26 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
CA2450167A1 (en) 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
EP2336133A1 (en) 2001-10-30 2011-06-22 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
EP1450784A4 (en) 2001-11-09 2005-02-09 Conforma Therapeutics Corp HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE
BR0308056A (pt) 2002-02-28 2004-12-07 Astrazeneca Ab Composto, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para a preparação de um composto
CA2522700A1 (en) 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
EA010160B1 (ru) 2003-09-18 2008-06-30 Конформа Терапьютикс Корпорейшн Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
EP1962863A4 (en) * 2005-12-22 2010-11-24 Conforma Therapeutics Corp ORALLY ACTIVE PURINE INHIBITORS OF THERMAL SHOCK PROTEIN 90
CA2652263A1 (en) 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
CA2656202C (en) * 2006-06-30 2018-01-16 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
US20080221132A1 (en) 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
FR2906824B1 (fr) 2006-10-09 2008-12-26 Roger Mondelin Sas Soc Par Act Dispositif support de butees pour la pose de plaques de platre de largeur variable avec des appareils de levage et de manutention desdites plaques
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
GB0622084D0 (en) * 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
US20080234297A1 (en) 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
US8324240B2 (en) * 2007-03-20 2012-12-04 Curis, Inc. Fused amino pyridine as HSP90 inhibitors
US20100240656A1 (en) 2007-07-12 2010-09-23 Oryzon Genomics, S.A. Compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
WO2009065035A1 (en) 2007-11-14 2009-05-22 Myriad Genetics, Inc. Therapeutic compounds and their use in treating diseases and disorders
EP2387316A4 (en) 2009-01-16 2012-06-13 Curis Inc CONDENSED AMINOPYRIDINE FOR THE TREATMENT OF BRAIN TUMORS
LT2486039T (lt) 2009-10-07 2016-10-10 Sloan Kettering Institute For Cancer Research Purino dariniai, naudingi kaip hsp90 slopikliai
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
KR101984480B1 (ko) 2011-04-05 2019-05-31 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 억제제
MX370664B (es) 2013-08-16 2019-12-19 Memorial Sloan Kettering Cancer Center Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.

Also Published As

Publication number Publication date
CN103582642B (zh) 2021-05-11
WO2012138894A4 (en) 2012-12-06
US9346808B2 (en) 2016-05-24
JP2014510148A (ja) 2014-04-24
BR112013025634A2 (pt) 2016-07-19
EP2694505B1 (en) 2022-04-27
CA2832530C (en) 2021-02-16
WO2012138894A1 (en) 2012-10-11
AU2012240077C1 (en) 2017-08-10
EA201391334A1 (ru) 2014-06-30
EP2694505A1 (en) 2014-02-12
NZ616758A (en) 2016-01-29
AU2012240077B2 (en) 2017-04-20
US20140088121A1 (en) 2014-03-27
CN103582642A (zh) 2014-02-12
AU2012240077A1 (en) 2013-10-31
KR20140062429A (ko) 2014-05-23
US9926321B2 (en) 2018-03-27
MX2013011532A (es) 2014-08-22
KR102010222B1 (ko) 2019-08-13
US20160264577A1 (en) 2016-09-15
JP6266506B2 (ja) 2018-01-24
CA2832530A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
MX360390B (es) Inhibidores de la proteina 90 de choque termico (hsp90).
NZ603155A (en) Phospholipid drug analogs
EA201391337A1 (ru) Ингибиторы hsp90
MX349159B (es) Derivados deuterados de ivacaftor.
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
PH12015500513A1 (en) Methods for the treatment of locally advanced breast cancer
WO2010132999A8 (en) Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
PH12016500164A1 (en) Therapeutically active compounds and their methods of use
MX2013012588A (es) Inhibidores de cinasa.
NZ726366A (en) Syk inhibitors
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
WO2012078757A3 (en) Combination for breast cancer therapy with hsp90 inhibitory compounds
MX338554B (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
WO2012141796A3 (en) Prostate cancer therapy with hsp90 inhibitory compounds
IN2014DN08886A (es)
MX2011008910A (es) Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson.
MX2013003638A (es) Tratamiento en combinacion para rosacea.
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
EA201270347A1 (ru) Производные апогоссиполона в качестве противоопухолевых агентов
IN2014KN01113A (es)
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
MX345264B (es) Derivado de azol.

Legal Events

Date Code Title Description
FG Grant or registration